Lutathera and Pluvicto

The Medical Readiness Contracting Office-West is issuing this Sources Sought Notice on behalf of Brooke Army Medical Center ( BAMC) JBSA - Fort Sam Houston, Texas. Any responses to this Sources Sought Notice will be used for planning purposes only. Based on the responses to this notice, the requirement may be set-aside for small businesses, procured through full-and-open competition, or result in a sole-source contract. The proposed North American Industry Classification System (NAICS) Code is 325412 with a corresponding size standard of 1,250 employees. This notice is not a solicitation of offers, nor is it a notice to proceed. BAMC has a requirement for  LUTATHERA and PLUVICTO doses. This requirement is for two FDA Approved products. Lutathera, is indicated for the imaging and treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors. Pluvicto is for the treatment of adult patients with prostrate specific membrane antigen-positive metastatic castration-resistant prostate cancer. Medications will be delivered from 01October 2023- 30 September 2027.

Salient Characteristics:

Lutetium Lu-177 Dotatate (Lutathera)

Must be FDA approved.

Must be Lu-177 Dotatate

Must be indicated for treatment of somatostatin receptor-positive gastroenterpancreatic neuroendocrine tumors, including foregut, midgut, and hindgut neuroendocrine tumors.

Should be a 4 dose treatment regimen given every 8 weeks.

Lutetium Lu-177 Vipivotide Tetraxetan (Pluvicto)

Must be FDA approved

Must be Lu-177 Vipivotide Tetraxetan

Must be indicated for treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC).

Should be a treatment regimen of every 6 weeks for up to 6 doses.

If your organization has the potential capacity to provide Lutathera, please provide the following information:

1) Organization name, address, e-mail address, Web site address, telephone number, and size (small versus large business, and any other socio-economic categories) and type of ownership for the organization;

2) Tailored capability statements addressing the particulars of this effort, with appropriate documentation supporting claims of organizational capability, to include proof of authorization to provide supplies and analyzer as well as maintenance and repair services on above-listed equipment. THERE IS NO SOLICITATION AT THIS TIME. This request for capability information does not constitute a request for proposals; submission of any information in response to this notice is purely voluntary; the Government assumes no financial responsibility for any costs incurred.

Contractors responding to this sources sought notice are advised their response does not ensure participation in future solicitations or contract awards.  The Government will not reimburse any company or individual for any expense associated with preparation or participation in this research.  Interested parties should e-mail responses to cicely.d.simmons-carroll.civ@health.mil by the date identified below.